Acadia Pharmaceuticals, Inc. (ACAD) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $23.79 +1.84%
Revenue Growth %: +12.1%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +12.1%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) reported Q2 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $460 thousand versus the consensus estimate of $480 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- Jefferies Financial Group (JEF) Misses Q2 EPS by 22c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
